Resverlogix Corp (RVX)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013617)
◆英語タイトル:Resverlogix Corp (RVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013617
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:32
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Resverlogix Corp (Resverlogix) is an epigenetics company that develops small molecule therapeutics for Bromodomain and ExtraTerminal Domain (BET) inhibition. The company provides lead product such as RVX-208 (apabetalone), is a BET inhibitor under phase III clinical trial. Its RVX-208 is being developed for high-risk cardiovascular disease patients with diabetes mellitus and low HDL; and Alzheimer’s disease. Resverlogix utilizes an epigenetics drug development platform, BET technology, to target BET proteins and identify small molecule candidates that specifically bind to BET bromodomains and regulate gene expression, among others. The company operates through its representative office in San Francisco, California, the US. Resverlogix is headquartered in Calgary, Alberta, Canada.

Resverlogix Corp (RVX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Resverlogix Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Resverlogix Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Resverlogix Corp, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Resverlogix Enters into Research Agreement with Emerald Logic 10
Licensing Agreements 11
Hepalink USA to Enter into Licensing Agreement with Resverlogix 11
Resverlogix Enters into Licensing Agreement with Shenzhen Hepalink Pharma 12
Equity Offering 13
Resverlogix to Raise USD69.8 Million in Private Placement of Units 13
Resverlogix to Raise USD3.6 Million in Private Placement of Units 14
Resverlogix Raises USD3.4 Million in Public Offering of Units 15
Resverlogix Raises USD4 Million in Private Placement of Units 16
Resverlogix Raises USD41.4 Million in Private Placement of Units 18
Resverlogix Raises USD2 Million in Private Placement of Shares 19
Resverlogix Completes Private Placement Of Units For US$1.5 Million 20
Resverlogix Completes Spin-Off of Zenith Epigenetics 21
Resverlogix Completes First Tranche Of Private Placement Of Shares For US$0.2 Million 22
Resverlogix Completes Private Placement Of Shares For US$16.9 Million 23
Resverlogix Completes Public Offering Of Units For US$13 Million 24
Resverlogix Corp – Key Competitors 25
Resverlogix Corp – Key Employees 26
Resverlogix Corp – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Corporate Communications 28
Apr 04, 2016: Resverlogix Further Strengthens the Board of Directors and Appoints a New Chairman 28
Product News 29
06/02/2016: Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016 29
05/24/2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association – European Dialysis & Transplant Association Congress (ERA-EDTA) 30
01/25/2016: Resverlogix Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Resverlogix Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Resverlogix Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Resverlogix Corp, Deals By Therapy Area, 2011 to YTD 2017 8
Resverlogix Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Resverlogix Enters into Research Agreement with Emerald Logic 10
Hepalink USA to Enter into Licensing Agreement with Resverlogix 11
Resverlogix Enters into Licensing Agreement with Shenzhen Hepalink Pharma 12
Resverlogix to Raise USD69.8 Million in Private Placement of Units 13
Resverlogix to Raise USD3.6 Million in Private Placement of Units 14
Resverlogix Raises USD3.4 Million in Public Offering of Units 15
Resverlogix Raises USD4 Million in Private Placement of Units 16
Resverlogix Raises USD41.4 Million in Private Placement of Units 18
Resverlogix Raises USD2 Million in Private Placement of Shares 19
Resverlogix Completes Private Placement Of Units For US$1.5 Million 20
Resverlogix Completes Spin-Off of Zenith Epigenetics 21
Resverlogix Completes First Tranche Of Private Placement Of Shares For US$0.2 Million 22
Resverlogix Completes Private Placement Of Shares For US$16.9 Million 23
Resverlogix Completes Public Offering Of Units For US$13 Million 24
Resverlogix Corp, Key Competitors 25
Resverlogix Corp, Key Employees 26
Resverlogix Corp, Other Locations 27

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Resverlogix Corp (RVX)-製薬・医療分野:企業M&A・提携分析(Resverlogix Corp (RVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆